H-NKGENAQAI-OH
Ref. 3D-PP44162
1mg | 217,00 € | ||
10mg | 253,00 € | ||
100mg | 455,00 € |
Informations sur le produit
- NH2-Asn-Lys-Gly-Glu-Asn-Ala-Gln-Ala-Ile-OH
Peptide H-NKGENAQAI-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-NKGENAQAI-OH include the following: Identification of a novel tumor-specific CTL epitope presented by RMA, EL-4, and MBL-2 lymphomas reveals their common origin T van Hall , J van Bergen, PA van Veelen - The Journal of , 2000 - journals.aai.orghttps://journals.aai.org/jimmunol/article/165/2/869/32951 Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants T van Hall , EZ Wolpert, P van Veelen, S Laban - Nature medicine, 2006 - nature.comhttps://www.nature.com/articles/nm1381 Effective immunotherapy of cancer in MUC1-transgenic mice using clonal cytotoxic T lymphocytes directed against an immunodominant MUC1 epitope LC Heukamp, T van Hall , F Ossendorp - Journal of , 2002 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/fulltext/2002/01000/effective_immunotherapy_of_cancer_in.5.aspx Identification of a Novel Tumor-Specific CTL CJM Melief , F Ossendorp , R Offringa, M Kraakman - J , 2000 - researchgate.nethttps://www.researchgate.net/profile/Lukas-Heukamp/publication/237234565_Origin_Lymphomas_Reveals_Their_Common_Presented_by_RMA_EL4_and_MBL2_Tumor-Specific_CTL_Epitope_Identification_of_a_Novel/links/0c96052789a5f06159000000/Origin-Lymphomas-Reveals-Their-Common-Presented-by-RMA-EL4-and-MBL2-Tumor-Specific-CTL-Epitope-Identification-of-a-Novel.pdf Pathways accessory to proteasomal proteolysis are less efficient in major histocompatibility complex class I antigen production B Kessler , X Hong, J Petrovic , A Borodovsky - Journal of Biological , 2003 - ASBMBhttps://www.jbc.org/article/S0021-9258(19)32470-6/abstract Induction of protective CTL immunity against peptide transporter TAP-deficient tumors through dendritic cell vaccination B Chambers, P Grufman, V Fredriksson, K Andersson - Cancer research, 2007 - AACRhttps://aacrjournals.org/cancerres/article-abstract/67/18/8450/533487
Propriétés chimiques
Question d’ordre technique sur : 3D-PP44162 H-NKGENAQAI-OH
Si vous souhaitez demander un devis ou passer commande, veuillez plutôt ajouter les produits souhaités à votre panier, puis demander un devis ou passer commande à partir de votre panier. C'est une méthode plus rapide, plus économique, et vous pourrez bénéficier des remises disponibles ainsi que d'autres avantages